IFX/AZA benefits outweigh risks in Crohn's disease, analysis finds

12/30/2011 | DoctorsLounge.com

Combined treatment with infliximab and azathioprine for one year appears to produce more benefits than risks among Crohn's disease patients, according to an analysis in Clinical Gastroenterology and Hepatology. Researchers found that the IFX/AZA combination was more effective than IFX monotherapy in treating the disease. The study was based on data from the Study of Biologic and Immunomodulator-Naive Patients With Crohn's Disease.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID